Jenny Valladeau-Guilemond

7PUBLICATIONS
34CO-AUTHORS
Tumour immunologyMolecular targetsInnate immunityCellular immunologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 18, 2026
Melanoma cell states shape spatial tumor-immune ecosystems to dictate the efficacy of anti-PD1 immunotherapy.

|Aug 04, 2025
HERV-derived epitopes represent new targets for T-cell-based immunotherapies in ovarian cancer.

Paola Bonaventura, Audrey Page, Olivier Tabone

|Mar 29, 2025
Type III interferon primes pDCs for TLR7 activation and antagonizes immune suppression mediated by TGF-β and PGE2.

Candice Sakref, Alexis Saby, Céline Rodriguez

|Jan 08, 2025
The Spatial Organization of cDC1 with CD8+ T Cells is Critical for the Response to Immune Checkpoint Inhibitors in Patients with Melanoma.

Elisa Gobbini, Margaux Hubert, Anne-Claire Doffin

|Jul 08, 2022
Direct T-cell Presentation by cDC1: The Key Feature for Cancer Vaccine Success?

Margaux Hubert, Christophe Caux, Jenny Valladeau-Guilemond

|Apr 19, 2020
IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer.

Margaux Hubert, Elisa Gobbini, Coline Couillault

Pageof 2

Frequent Collaborators

4 joint publications

Margaux Hubert

3 joint publications

Christophe Caux

2 joint publications

Elisa Gobbini

2 joint publications

Justine Berthet